To determine whether ER signaling activity is a prognostic marker or a biomarker for endocrine therapy response, we first classified samples of breast, ovarian, endometrial, and cervical cancers in the TCGA data sets as having low or high ER signaling activity by determining the EERESs for each sample as described in the “Methods” section. This evidence concerns the gene ESR1 and cervical carcinoma.